The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 04, 2026

Filed:

Jul. 10, 2020
Applicant:

Miltenyi Biotec B.v. & Co. KG, Bergisch Gladbach, DE;

Inventors:

Nicole Cordes, Bergisch Gladbach, DE;

Thomas Schaser, Bergisch Gladbach, DE;

Andrew Kaiser, Bergisch Gladbach, DE;

Assignee:

MILTENYI BIOTEC B.V. & CO. KG, Bergisch Gladbach, DE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/725 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/705 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 15/62 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 40/4224 (2025.01); C07K 16/30 (2013.01); C12N 5/0636 (2013.01); C12N 15/625 (2013.01); C12N 15/86 (2013.01); C12N 2502/1107 (2013.01); C12N 2740/15023 (2013.01); C12N 2740/15042 (2013.01); C12N 2830/002 (2013.01);
Abstract

The present invention provides an in-vitro method of reducing the efficiency of transducing malignant cells of the blood system of a subject that are not derived from T cells with lentiviral vector particles without reducing the efficiency of transducing T cells in a sample comprising T cells and said malignant cells. A combination of compositions comprising a first composition and a second composition is also disclosed, wherein said first composition comprises i) transduced T cells of a subject, wherein said transduced T cells express a CAR comprising an antigen binding domain, wherein the antigen binding domain of said CAR binds specifically to a tag of a tagged polypeptide, and ii) non-transduced malignant cells of the blood system of said subject, and wherein said second composition comprises said tagged polypeptide, wherein said tagged polypeptide binds specifically to an antigen expressed on the surface of said malignant cells. Alternatively, the transduced T cells of said first composition may comprise a nucleic acid encoding a CAR and an inducible gene expression system, and said second composition may comprise an induction agent inducing said gene system.


Find Patent Forward Citations

Loading…